Scarica l'app Stockscreener
1.14
6.56%
-0.08
Dopo l'orario di chiusura:
1.17
0.03
+2.63%
Precedente Chiudi:
$1.22
Aprire:
$1.21
Volume 24 ore:
52,157
Relative Volume:
0.29
Capitalizzazione di mercato:
$64.52M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.6404
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
-12.98%
1M Prestazione:
+34.78%
6M Prestazione:
+54.05%
1 anno Prestazione:
-77.99%
Intervallo 1D:
$1.12
$1.21
Intervallo di 1 settimana:
$1.1042
$1.30
Portata 52W:
$0.6101
$5.53
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.14 | 63.96M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Is Prelude Therapeutics Incorporated backed by strong institutional buyingJuly 2025 Movers & Daily Volume Surge Trade Alerts - khodrobank.com
Real time social sentiment graph for Prelude Therapeutics IncorporatedEarnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Prelude Therapeutics Incorporated stock outlook for YEAR2025 Macro Impact & Daily Stock Momentum Reports - Newser
Prelude Therapeutics Incorporated stock trend forecast2025 Retail Activity & Free Daily Entry Point Trade Alerts - Newser
Does Prelude Therapeutics Incorporated fit your quant trading modelEarnings Recap Report & Daily Growth Stock Tips - Newser
Published on: 2025-09-03 02:57:37 - Newser
Real time scanner hits for Prelude Therapeutics Incorporated explainedMarket Performance Report & Long-Term Capital Growth Ideas - Newser
What’s next for Prelude Therapeutics Incorporated stock priceQuarterly Market Review & Stepwise Trade Execution Plans - Newser
How sentiment analysis helps forecast Prelude Therapeutics IncorporatedJuly 2025 Drop Watch & Advanced Technical Signal Analysis - Newser
Will Prelude Therapeutics Incorporated continue its uptrend2025 Earnings Impact & Technical Pattern Recognition Alerts - Newser
How to interpret RSI for Prelude Therapeutics Incorporated stockJuly 2025 Earnings & Consistent Growth Equity Picks - Newser
Visual trend scoring systems applied to Prelude Therapeutics IncorporatedJuly 2025 Update & Daily Price Action Insights - Newser
Is now a turning point for Prelude Therapeutics IncorporatedMarket Performance Report & AI Powered Buy and Sell Recommendations - Newser
Does Prelude Therapeutics Incorporated meet Warren Buffett’s criteriaWeekly Investment Summary & Daily Stock Momentum Reports - khodrobank.com
Is Prelude Therapeutics Incorporated stock forming a cup and handleJuly 2025 Big Picture & Short-Term High Return Strategies - khodrobank.com
Investment Review: What drives Prelude Therapeutics Incorporated’s stock priceWeekly Risk Report & Smart Swing Trading Alerts - khodrobank.com
Is Prelude Therapeutics Incorporated still worth holding after the dipPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
Prelude Therapeutics Incorporated stock volume spike explained2025 Fundamental Recap & AI Driven Stock Price Forecasts - Newser
Will Prelude Therapeutics Incorporated outperform the marketJuly 2025 News Drivers & Proven Capital Preservation Tips - Newser
Can Prelude Therapeutics Incorporated keep up with sector leadersWeekly Trading Summary & Daily Volume Surge Signals - khodrobank.com
Evaluating Prelude Therapeutics Incorporated with trendline analysisWeekly Stock Recap & Weekly High Conviction Trade Ideas - Newser
Can Prelude Therapeutics Incorporated continue delivering strong returns2025 Market Sentiment & Pattern Based Trade Signal System - khodrobank.com
What are the risks of holding Prelude Therapeutics IncorporatedWeekly Investment Summary & Long-Term Safe Return Strategies - kpenews.com
What candlestick patterns are forming on Prelude Therapeutics Incorporated2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - Newser
Prelude Therapeutics’ SWOT analysis: cancer drug developer’s stock faces pivotal phase - Investing.com
Bollinger Bands Show Potential Breakout in Prelude Therapeutics Incorporated getLinesFromResByArray error: size == 0 - news-j.co.kr
What MACD signals say about Prelude Therapeutics IncorporatedWeekly Gains Summary & Risk Managed Trade Strategies - Newser
Detecting price anomalies in Prelude Therapeutics Incorporated with AITrade Signal Summary & Growth Oriented Trading Recommendations - Newser
How to manage a losing position in Prelude Therapeutics IncorporatedBond Market & Safe Entry Point Alerts - Newser
Has Prelude Therapeutics Incorporated formed a bullish divergence2025 Winners & Losers & Precise Trade Entry Recommendations - Newser
What to expect from Prelude Therapeutics Incorporated in the next 30 daysJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Prelude Therapeutics Incorporated Crosses 200 Day MA — Signal or Noise2025 Major Catalysts & Long-Term Capital Growth Strategies - beatles.ru
Published on: 2025-08-31 01:19:53 - Newser
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prelude Therapeutics Inc Azioni (PRLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):